Recombinant Anti-F8 Mab (HOM-19284)
|Recombinant Human Anti-Human F8 Monoclonal Antibody
- Product Overview
- Recombinant humanized antibody expressed in CHO binding to human F8.
- ELISA, WB, IHC, FCM, IP, IF. Optimal dilutions/concentrations should be determined by the end user.
- Molecular Weight
- 145.41 kDa
- >95.0% as determined by analysis by RP-HPLC & analysis by SDS-PAGE.
- Store it under sterile conditions at -20 °C upon receiving. Recommend to pack the antibody into smaller quantities for optimal storage.
- Samples are stable for up to twelve months from date of receipt at - 20°C and are stable for six months at 4 °C.
- Antigen Description
- Factor VIII (FVIII) is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene. Defects in this gene results in hemophilia A, a recessive X-linked coagulation disorder. Factor VIII is produced in liver sinusoidal cells and endothelial cells outside of the liver throughout the body. This protein circulates in the bloodstream in an inactive form, bound to another molecule called von Willebrand factor, until an injury that damages blood vessels occurs. In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. The active protein (sometimes written as coagulation factor VIIIa) interacts with another coagulation factor called factor IX. This interaction sets off a chain of additional chemical reactions that form a blood clot.
- copper ion binding; metal ion binding; oxidoreductase activity; protein binding;
- F8; coagulation factor VIII, procoagulant component; F8C; coagulation factor VIII; DXS1253E; Factor VIIIF8B; FVIII; HEMA; hemophilia A; factor VIII F8B; antihemophilic factor; coagulation factor VIIIc; AHF; F8B;
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.